Salcaprozate sodium
Based on 4 publication(s) in Google Scholar
Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.95%
- CAS 番号: 203787-91-1
- 分子式: C15H20NNaO4
- 分子量:301.32
-
保管条件:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-115340
Decanoic acid sodiumBiochemical Assay Reagent -
HY-10583
Y-27632 dihydrochlorideROCK Inhibitor -
HY-114299R
Salcaprozate sodium (Standard)Absorption Promoter -
HY-13259
MG-132Proteasome Inhibitor -
HY-10219
RapamycinmTOR Inhibitor -
HY-114118
SemaglutideGLP-1R Agonist -
HY-15531
VenetoclaxBCL-2 Inhibitor -
HY-P0035
Insulin (human)Recombinant Human Insulin -
HY-100558
Bafilomycin A1V-ATPase Inhibitor -
HY-12270
T-5224c-Fos/AP-1 Inhibitor -
HY-112693
H-151STING Antagonist -
HY-Y0873
PEG300Neutral Polymer
MedChemExpress（MCE）の使用を引用している文献 Salcaprozate sodium
More
Customer Validation & Images
-
PK/PD Analysis
-
Bio/Physico-chemical Assay
生物活性
製品説明
体外実験
SNAC (12.5-400 μg/mL; 24 h) has no toxicity to Caco-2 cells, and the survival percentage is above 90% when SNAC is 200 μg/mL[3].
SNAC (50 and 200 μg/mL) improves the apparent permeability coeffcient (Papp) of RA and SA-B by 2.14-fold and 3.68-fold compared with the Papp of SAs solution[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
体内実験
SNAC (2000 mg/kg/d; oral gavage for 13 weeks) related mortality is evident only at the 2000-mg/kg/d level, 20% among males and 50% among females; no clear cause of death is evident[1].
SNAC (100-1000 mg/kg/d; oral gavage for 13 weeks) induces no mortality in the Wistar rat study at doses up to 1000 mg/kg/d[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (6-7 weeks)[1]
-
Dosage:2000 mg/kg/d
-
Administration:Oral gavage for 13 weeks
-
Result:Induced 20% and 50% mortality in males and females at the dose of 2000 mg/kg/d.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 203787-91-1
-
性状 Solid
-
分子量 301.32
-
分子式 C15H20NNaO4
-
Color White to off-white
-
SMILES
O=C(O[Na])CCCCCCCNC(C1=CC=CC=C1O)=O
-
別名
SNAC
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Carbohydr Polym
Oral efficacy of structurally defined chondroitin sulfate Co-administered with SNAC in Parkinson's disease. [Abstract]2026 Jan 1:371:124492. PMID: 41198308
Salcaprozate sodium purchased from MedChemExpress. Usage Cited in: Carbohydr Polym. 2026 Jan 1:371:124492. [Abstract]
Effects of oral administration of CS-dp8-de6S (100 mg/kg) in combination with SNAC (100 mg/kg) on body weight, AST, ALT, CREA and BUN.
-
ACS Omega
Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]2024 Feb 28;9(10):11870-11882. PMID: 38496939 -
-
Pharm Res
Modification of Peptide and Permeation Enhancer In Vitro Release Rates by Dispersion with a Gel-Forming Polymer. [Abstract]2025 Jun;42(6):1003-1020. PMID: 40481297
Salcaprozate sodium purchased from MedChemExpress. Usage Cited in: Pharm Res. 2025 Jun;42(6):1003-1020. [Abstract]
Fluorescence spectra of SNAC at different concentrations.
溶剤 & 溶解度
体外:
H2O : 50 mg/mL (165.94 mM; Need ultrasonic)
DMSO : 50 mg/mL (165.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
プロトコル
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
純度とドキュメンテーション
-
データシート (272 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Riley MGI, et, al. Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats. Int J Toxicol. Jul-Aug 2009; 28(4):278-93. [Content Brief]
[2]. Twarog C, et, al. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C 10). Pharmaceutics. 2019 Feb 13; 11(2):78. [Content Brief]
[3]. Li Y, et, al. Impact of Sodium N-[8-(2-Hydroxybenzoyl)amino]-caprylate on Intestinal Permeability for Notoginsenoside R1 and Salvianolic Acids in Caco-2 Cells Transport and Rat Pharmacokinetics. Molecules. 2018 Nov 16; 23(11):2990. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.3188 mL | 16.5938 mL | 33.1875 mL | 82.9688 mL |
| 5 mM | 0.6638 mL | 3.3188 mL | 6.6375 mL | 16.5938 mL | |
| 10 mM | 0.3319 mL | 1.6594 mL | 3.3188 mL | 8.2969 mL | |
| 15 mM | 0.2213 mL | 1.1063 mL | 2.2125 mL | 5.5313 mL | |
| 20 mM | 0.1659 mL | 0.8297 mL | 1.6594 mL | 4.1484 mL | |
| 25 mM | 0.1328 mL | 0.6638 mL | 1.3275 mL | 3.3188 mL | |
| 30 mM | 0.1106 mL | 0.5531 mL | 1.1063 mL | 2.7656 mL | |
| 40 mM | 0.0830 mL | 0.4148 mL | 0.8297 mL | 2.0742 mL | |
| 50 mM | 0.0664 mL | 0.3319 mL | 0.6638 mL | 1.6594 mL | |
| 60 mM | 0.0553 mL | 0.2766 mL | 0.5531 mL | 1.3828 mL | |
| 80 mM | 0.0415 mL | 0.2074 mL | 0.4148 mL | 1.0371 mL | |
| 100 mM | 0.0332 mL | 0.1659 mL | 0.3319 mL | 0.8297 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Salcaprozate sodium 関連分類
HY-114299 関連分類
Powered by Bioz